Diseases of the Esophagus

Papers
(The TQCC of Diseases of the Esophagus is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
29: INCIDENCE, DIAGNOSIS AND MANAGEMENT OF MALABSORPTION FOLLOWING OESOPHAGECTOMY: A SYSTEMATIC REVIEW34
369 POOR CORRELATION BETWEEN FDG-PET AND PATHOLOGIC RESULTS AFTER EXPERIMENTAL NEOADJUVANT IMMUNOCHEMOTHERAPY FOR GASTROESOPHAGEAL ADENOCARCINOMA: RESULTS OF A CLINICAL TRIAL30
723 TWO- VS. THREE-FIELD LYMPHADENECTOMY FOR ESOPHAGEAL CANCER. A SYSTEMATIC REVIEW AND META-ANALYSIS OF SHORT- AND LONG-TERM OUTCOMES.29
834 ENDOSCOPIC VACUUM THERAPY IN THE MANAGEMENT OF OESOPHAGEAL PERFORATIONS AND POST-OPERATIVE LEAKS26
173. FEASIBILITY AND POTENTIAL ADVANTAGE OF ROBOT-ASSISTED ESOPHAGECTOMY FOR CT4B ESOPHAGEAL CANCER25
321. ESD AND ELPS A NOVEL MINIMALLY INVASIVE TREATMENT FOR MULTI-EPISODE SUPERFICIAL ESOPHAGEAL SCC AND 2ND PRIMARY HYPOPHARYNGEAL SCC:A CASE REPORT25
408. COMPARISON OF THE SHORT-TERM EFFICACY OF THORACOSCOPY COMBINED WITH GASTROSCOPY AND TRADITIONAL THORACOTOMY IN THE TREATMENT OF SPONTANEOUS ESOPHAGEAL RUPTURE24
411. SINGLE-PORT THORACOSCOPIC RESECTION FOR THE SPINDLE CELL TUMOR OF ESOPHAGUS23
280. FEASIBILITY OF ROBOTIC-ASSISTED SURGERY FOR BENIGN ESOPHAGEAL LESIONS: SINGLE-CENTER EXPERIENCE22
745 YIELD OF EXTENDED AND TOTAL MEDIASTINAL LYMPHADENECTOMY IN OESOPHAGEAL CANCER19
618 STUDY ON THE RELATIONSHIP BETWEEN GASTROESOPHAGEAL REFLUX SYMPTOMS AND ESOPHAGEAL MICROBIOTA18
687 ADVERSE EVENTS DURING MINIMALLY INVASIVE ESOPHAGECTOMY IN PRONE POSITION18
626 ENDOSCOPIC VACUUM THERAPY FOR ANASTOMOTIC LEAK IN ESOPHAGECTOMY AND TOTAL GASTRECTOMY: A SYSTEMATIC REVIEW AND META-ANALYSIS18
Novel histologic score predicts recurrent intestinal metaplasia after successful endoscopic eradication therapy15
166 CLINICAL IMPACT OF NEW BIOMARKERS IN THE PATIENTS WITH ESOPHAGEAL CARCINOMA15
Diagnostic differences in high-resolution esophageal motility in a large Mexican cohort based on geographic distribution14
Correction to: Radial incision and cutting for dilation before endoscopic submucosal dissection in patients with esophageal cancer on the distal side of severe benign esophageal strictures14
Trends and predictors of 30-day readmissions in subjects with eosinophilic esophagitis: results from a national cohort13
643. PRACTICAL IMAGING REVIEW OF EXPECTED FINDINGS AND POSSIBLE COMPLICATIONS RELATED TO MULTIMODAL TREATMENT OF ESOPHAGEAL CANCER13
The efficacy of adjuvant chemotherapy with capecitabine and cisplatin after surgery in locally advanced esophageal squamous cell carcinoma: a multicenter randomized phase III trial13
245. CLINICAL UTILITY OF CTDNA IN LONGITUDINAL MONITORING OF TREATMENT RESPONSES AND RELAPSE IN METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA12
266. EXTENSION OF FDG-PET-BASED RADIOMIC MODELS ON IDENTIFICATION OF PATIENTS WITH RESIDUAL ESOPHAGEAL CANCER AFTER NEOADJUVANT CHEMORADIOTHERAPY12
539. SURGICAL TECHNIQUES AND OUTCOMES OF GASTRIC CONDUIT RECONSTRUCTION FOLLOWING ESOPHAGECTOMY BY HAND-ASSISTED LAPAROSCOPIC SURGERY (HALS) FOR ESOPHAGEAL CANCER12
369. GENOMIC ALTERATIONS AND SURVIVAL AFTER TREATMENT OF EAC BY SURGERY WITHOUT CHEMO- OR RADIOTHERAPY12
594. TOTALLY MINIMALLY INVASIVE 2-STAGE ESOPHAGECTOMY VERSUS HYBRID 2-STAGE ESOPHAGECTOMY. A SINGLE CENTER EXPERIENCE12
538. A DECADE OF ESOPHAGEAL AND ESOPHAGO-GASTRIC JUNCTION CANCER EPIDEMIOLOGY IN NATIONAL CANCER INSTITUTE MEXICO12
461. SURGICAL TREATMENT OF STAGE IV ESOPHAGEAL CANCER AFTER CCRT IMPROVES SURVIVAL11
239. EVALUATION OF SUBCARINAL LYMPH NODE DISSECTION AND METASTASIS IN TRANSMEDIASTINAL RADICAL ESOPHAGECTOMY11
523. RISK FACTORS ASSOCIATED WITH NOT RECEIVING ADJUVANT CHEMOTHERAPY FOR LOCALLY ADVANCED ESOPHAGOGASTRIC ADENOCARCINOMA11
570. ADRENAL METASTASES OF ESOPHAGEAL CANCER: SURGICAL MANAGEMENT OF SINGLE METASTASES10
793. MODIFIED HELLER DOR FOR ACHALASIA10
294. LEARNING CURVE OF MINIMALLY INVASIVE ESOPHAGECTOMY: OUR SERIES, SYSTEMATIC REVIEW OF THE LITERATURE AND META-ANALYSIS10
535. AUDITING THE PATIENTS OUTCOMES AFTER SURGERY FOR ESOPHAGEAL AND GASTRIC CARDIA CANCER WITHIN THE 18 YEARS PERIOD. SINGLE CENTER EXPERIENCE10
803. 2-YEAR RESULTS IN ESOPHAGOGASTRIC JUNCTION CANCER TREATMENT10
739. SIGNIFICANCE OF COX2 INHIBITOR FOR ESOPHAGEAL CANCER FROM THE CLINICAL AND EXPERIMENTAL ESTIMATE10
Pressure dynamics of the esophagogastric junction at rest and during inspiratory maneuvers after Nissen fundoplication9
147. CHARACTERISTICS AND PREDICTORS OF EARLY POSTOPERATIVE RECURRENCE OF ESOPHAGEAL CANCER9
765. PATTERNS, TIMING, AND SURVIVAL OF RECURRENCE FOLLOWING SURGERY FOR ESOPHAGEAL ADENOCARCINOMA IN THE EUROPEAN MULTICENTRE ENSURE STUDY9
Modified reconstruction procedure in subtotal esophagectomy with retrosternal gastric pull up to reduce anastomotic leakage: a propensity score-matched analysis9
Validation of the Swedish Watson Dysphagia Scale for adult patients with eosinophilic esophagitis9
158. PACLITAXEL PLUS CISPLATIN AND 5 FUOROURACIL INDUCTION CHEMOTHERAPY FOR BORDERLINE RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA: 3-YEAR SURVIVAL RESULT9
327. ANALYSING THE ROLE OF PET-CT IN ESOPHAGEAL CANCER: A SINGLE CENTRE COHORT STUDY9
226. PHILOSOPHICAL CONSIDERATIONS IN SURGICAL INNOVATION9
269. PATIENT-DERIVED TUMOR ORGANOIDS AND XENOGRAFTS AS BASIC AND PRECLINICAL TRANSLATIONAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MODELS9
Can FLIP guide therapy in idiopathic esophagogastric junction outflow obstruction?8
Management and outcomes of esophageal perforation8
793 PATIENTS’ PREFERENCES FOR ACTIVE SURVEILLANCE OR STANDARD ESOPHAGECTOMY AFTER NEOADJUVANT CHEMORADIOTHERAPY: A DISCRETE CHOICE EXPERIMENT IN PATIENTS AFTER STANDARD ESOPHAGECTOMY8
The broad impact of functional lumen imaging probe panometry in addition to high-resolution manometry in an esophageal clinical practice8
Management and outcomes in a consecutive series of patients with aero-digestive fistula at a tertiary gastro-esophageal surgery center8
255. EARLY COST-EFFECTIVENESS MODELLING STUDY COMPARING MINIMALLY INVASIVE TRANSCERVICAL ESOPHAGECTOMY (MICE) AND TRANSTHORACIC MINIMALLY INVASIVE ESOPHAGECTOMY (TMIE) IN OESOPHAGEAL CANCER PATIENTS8
The interventional esophagologist: tunneling a new way forward8
621 PL02.05 LONG-TERM TREATMENT OF PATIENTS WITH EOSINOPHILIC GASTRITIS AND/OR EOSINOPHILIC DUODENITIS WITH LIRENTELIMAB, A MONOCLONAL ANTIBODY AGAINST SIGLEC-88
523 STAGING PET-CT LENGTH AND SURVIVAL IN PATIENTS UNDERGOING RESECTIONS FOR ESOPHAGEAL ADENOCARCINOMA8
44. LONG-TERM OUTCOMES OF PERORAL ENDOSCOPIC MYOTOMY FOR PATIENTS WITH ACHALASIA: A SINGLE-CENTRE STUDY7
259. ROBOTIC ESOPHAGECTOMY AND THREE FIELD LYMPHADENECTOMY WITH INTRA-OPERATIVE RECURRENT LARYNGEAL NERVE MONITORING7
Follow-up and symptom persistence after esophageal food impaction7
178. OUTCOME OF DOCETAXEL, CISPLATIN, AND 5-FLUOROURACIL COMBINATION CHEMORADIOTHERAPY FOR LOCALLY ADVANCED ESOPHAGEAL CANCER7
189. IDENTIFICATION OF M6A-RELATED SIGNATURE GENES IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA BY MACHINE LEARNING METHOD7
228. THORACOACROMIAL ARTERY PERFORATOR FLAP REPAIR OF ACQUIRED INTRATHORACIC NONMALIGNANT TRACHEOESOPHAGEAL FISTULAS THROUGH A MIDSTERNAL INCISION APPROACH7
421. UNVEILING THE COMPLEXITY—DISSECTION OF 106 LYMPH NODES IN ESOPHAGEAL CANCER7
822 HOW THE OPERATING SURGEON'S ASSESSMENT OF RADICALITY INFLUENCES SURVIVAL AFTER ESOPHAGEAL CANCER SURGERY7
34. EXTENDED RIGHT THORACIC APPROACH COMPARED WITH LIMITED LEFT THORACIC APPROACH FOR ESOPHAGEAL CANCER: TEN-YEAR SURVIVAL OF A PROSPECTIVE RANDOMIZED TRIAL7
209: ROLE OF ADJUVANT CHEMOTHERAPY IN LOW BURDEN (YPT0-T1N0) GASTRIC ADENOCARCINOMA AFTER NEOADJUVANT CHEMOTHERAPY6
605. NEOADJUVANT FLOT FOR LOCALLY ADVANCED ESOPHAGEAL CANCERS: A SYSTEMATIC REVIEW AND META-ANALYSIS6
779 USE OF INDOCYANINE GREEN TO ASSESS THE CORRECT VASCULARIZATION OF GASTROPLASTY IN MCKWEON ESOPHAGECTOMY6
417. ROBOT-ASSISTED MINIMALLY INVASIVE ESOPHAGECTOMY WITH UPPER MEDIASTINAL LYMPHADENECTOMY6
472. ROUTINE PLACEMENT OF FEEDING TUBES SHOULD BE AVOIDED IN ESOPHAGEAL CANCER PATIENTS UNDERGOING SURGERY6
668 USEFULNESS OF PRONE-POSITION COMPUTED TOMOGRAPHY AS PREOPERATIVE SIMULATION OF THORACOSCOPIC ESOPHAGECTOMY FOR THORACIC ESOPHAGEAL CANCER6
278. SHORT- AND LONG-TERM OUTCOME AFTER UPFRONT SURGERY OR NEOADJUVANT CHEMOTHERAPY FOLLOWED BY SURGERY IN ELDERLY PATIENTS WITH RESECTABLE ESOPHAGEAL CANCER6
372. ASSESSMENT OF TUMOR REGRESSION GRADE IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA AFTER CHEMORADIOTHERAPY: COMPARISON OF 3 COMMONLY USED SCORING SYSTEMS6
478. ENDOSCOPIC RESECTION OF A HUGE ESOPHAGEAL LIPOSARCOMA WITH LIGASURE INSTRUMENT6
619. THE STRATEGY OF THE SURGICAL TREATMENT FOR ESOPHAGEAL NEUROENDOCRINE CARCINOMA6
516. MICRONUTRIENT DEFICIENCIES AFTER GASTROESOPHAGEAL CANCER SURGERY6
487. THE OUTCOME OF NIVOLUMAB THERAPY FOR PLATINUM-RESISTANT UNRESECTABLE ADVANCED OR RECURRENT ESOPHAGEAL CANCER6
207. THE EVOLUTION OF THE PERIOPERATIVE ENHANCED RECOVERY PROTOCOL IN ESOPHAGEAL SURGERY DURING 10 YEARS6
307. INGENUITY OF ESOPHAGOGASTRIC ANASTOMOSIS IN OUR DEPARTMENT -RECONSTRUCTED GASTRIC TUBE STUMP CLOSURE USING ENDO GIA RADIAL RELOAD6
502. CORRELATION OF LYMPH NODE SIZE WITH METASTATIC INVOLVEMENT IN PATIENTS WITH OESOPHAGEAL CANCER6
711 POST-REFLUX SWALLOW-INDUCED PERISTALTIC WAVE IS IMPAIRED IN LARYNGOPHARYNGEAL AND GASTRO-OESOPHAGEAL REFLUX DISEASE5
What is the significance of the Hill classification?5
How much progress have we made?: a 20-year experience regarding esophageal stents for the palliation of malignant dysphagia5
Performance of radiomics-based artificial intelligence systems in the diagnosis and prediction of treatment response and survival in esophageal cancer: a systematic review and meta-analysis of diagnos5
In vitro and in vivo evaluation of a novel wired transmission pH-combined photographic catheter for ambulatory gastroesophageal reflux monitoring (with videos)5
Characteristics analyses and tumor staging proposal for primary malignant melanoma of the esophagus: a retrospective study5
Clinical utility and applicability of circulating tumor DNA testing in esophageal cancer: a systematic review and meta-analysis5
Disruption of the brain–esophagus axis in obese patients with heartburn5
Feeding gastrostomy and duodenostomy using the round ligament of the liver versus conventional feeding jejunostomy after esophagectomy: a meta-analysis5
Laparoscopic total fundoplication is superior to medical treatment for reducing the cancer risk in Barrett’s esophagus: a long-term analysis5
189 GLUCOCORTICOID RECEPTOR AND SERUM- AND GLUCOCORTICOID-INDUCED KINASE-1 IN ESOPHAGEAL ADENOCARCINOMA AND ADJACENT BARRETT’S ESOPHAGUS5
Magnetic sphincter augmentation and high-resolution manometry: impact of biomechanical properties on esophageal motility and clinical significance for selection and outcomes5
Ki-67 overexpression for risk stratification of early dysplasia in Barrett’s esophagus: Friend or foe?5
Omission of intraoperative pyloric procedures in minimally invasive esophagectomy: assessing the impact on patients5
795. REVIEW OF CLINICAL CHARACTERISTICS AND PROGNOSIS OF MULTIPLE PRIMARY ESOPHAGEAL SQUAMOUS CELL CARCINOMA4
457. EVALUATING THE ACCURACY OF CLINICAL SIEWERT CLASSIFICATION, A RETROSPECTIVE REVIEW OF 807 PATIENTS4
Safety, efficacy, and cost-effectiveness of minimally invasive esophagectomies versus open esophagectomies: an umbrella review4
273. PERIOPERATIVE BLOOD TRANSFUSIONS AND SURVIVAL IN GASTROESOPHAGEAL CANCERS – A SWEDISH POPULATION-BASED STUDY4
546 INTENSIVE SURVEILLANCE AFTER CURATIVE INTENT SURGERY FOR ESOPHAGEAL CANCER: INITIAL RESULTS OF THE ENSURE STUDY4
378. LAPAROSCOPIC PRIMARY CLOSURE OF ESOPHAGEAL RUPTURE CAUSED BY BALLOON DILATATION FOR ACHALASIA AND HELLER'S MYOTOMY WITH DOR FUNDOPLICATION4
599. ASSESSMENT OF BREATHING MECHANICS IN OESOPHAGEAL CANCER SURVIVORS USING A 3D-MOTION CAPTURE SYSTEM4
466. ROBOT-ASSISTED CERVICAL ESOPHAGECTOMY (RACE) FOR ESOPHAGEAL CANCER: THE FIRST TWO CASES OF AN ITALIAN HIGH-VOLUME CENTER4
252. RIGHT GASTROEPIPLOIC ARTERY LENGTH DETERMINED ANASTOMOTIC LEAKRIGHT GASTROEPIPLOIC ARTERY LENGTH DETERMINED ANASTOMOTIC LEAKAGE AFTER MINIMALLY INVASIVE ESOPHAGECTOMY FOR ESOPHAGEAL CANCER-A PROS4
498. LATROGENIC ESOPHAGEAL DISEASE POST OBESITY TREATMENT: SEVERE ESOPHAGEAL DILATATION RELATED TO ADJUSTABLE GASTRIC BANDING (AGB)4
770. CLOSURE OF OESOPHAGEAL DEFECTS USING THE VACSTENT DEVICE: INITIAL INSIGHTS FROM THE LARGEST UK CASE SERIES4
326. SPONTANEOUS OESOPHAGEAL PERFORATION TREATED WITH OESOPHAGEAL STENT4
600. DETECTION OF ANASTOMOTIC LEAK THROUGH THE VALUE OF DRAIN FLUID AMYLASE4
489. EVALUATION OF THE ONCOLOGICAL QUALITY OF MINIMALLY INVASIVE TRANSCERVICAL OESOPHAGECTOMY (MICE) USING A CADAVERIC MODEL4
406. EXPLORING THE OPTIMAL TIMING OF MINIMALLY INVASIVE SURGERY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA AFTER NEOADJUVANT CHEMORADIOTHERAPY4
611. THE UTILITY OF H ANASTOMOSIS IN INFLATABLE MEDIASTINOSCOPE-ASSISTED TRANSHIATAL ESOPHAGECTOMY FOR ESOPHAGEAL CANCER4
420. MESH REINFORCEMENT IN HIATAL HERNIA REPAIR: CLINICAL RESULTS OF OUR EARLY EXPERIENCE4
777. COMBINED OESOPHAGEAL AND AIRWAY STENTING FOR MALIGNANT OESOPHAGEAL STRICTURES: THE UK’S LARGEST TERTIARY CENTRE EXPERIENCE AND DEVELOPMENT OF A NOVEL ALGORITHM4
Issues in histopathological reporting: a crucial crossroad between surgeons and pathologists after oesophago-gastrectomy4
Neoadjuvant versus definitive chemoradiation in locally advanced esophageal cancer for patients of advanced age or significant comorbidities4
632. CAN CARDIOPULMONARY EXERCISE TESTING PREDICT NEOADJUVANT CHEMOTHERAPY TOXICITY IN OESOPHAGEAL ADENOCARCINOMA PATIENTS?4
289. RISK FACTOR OF RELAPSE IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA WHO ACHIEVE PATHOLOGIC COMPLETE RESPONSE TO NEOADJUVANT CHEMORADIOTHERAPY3
703 SARCOPENIA OBESITY AND MYOSTEATOSIS ARE RISK FACTORS FOR COMPLICATIONS FOLLOWING RESECTION OF OESOPHAGOGASTRIC CANCERS3
674 TRANSITION FROM ESOPHAGECTOMY TO ENDOSCOPIC THERAPY FOR EARLY ESOPHAGEAL CANCER3
72 PHASE II ADJUVANT CANCER-SPECIFIC VACCINE THERAPY FOR ESOPHAGEAL CANCER PATIENTS CURATIVELY RESECTED AFTER PREOPERATIVE THERAPY WITH PATHOLOGICALLY POSITIVE NODES3
Gastroesophageal reflux disease following laparoscopic vertical sleeve gastrectomy and laparoscopic roux-en-Y gastric bypass: meta-analysis and systematic review of 5-year data3
342. GENOMIC ANALYSIS OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN OESOPHAGEAL ADENOCARCINOMA3
272. IMPLEMENTATION OF AN ERAS PROTOCOL IN PATIENTS UNDERGOING ESOPHAGECTOMY: EVALUATION OF THE RESULTS3
450 FACTORS AFFECTING CIRCUMFERENTIAL RESECTION MARGIN AFTER ESOPHAGECTOMY AND ITS PROGNOSTIC SIGNIFICANCE-LARGE SINGLE CENTRE EXPERIENCE3
260. EFFECT OF ENDOLUMINAL VACUUM THERAPY ON THE PERFUSION OF GASTRIC CONDUIT IN A PORCINE MODEL FOR ESOPHAGECTOMY3
648 APPLICATION OF THE GLOBAL LEADERSHIP INITIATIVE ON MALNUTRITION (GLIM) CRITERIA IN PERIOPERATIVE MANAGEMENT OF ESOPHAGEAL CANCER PATIENTS3
Comparing clinical outcomes of peroral endoscopic myotomy for achalasia between Eastern and Western countries: a systematic review and meta-analysis3
439. ACUTE GASTRIC VOLVULUS—LATE OCCURRENCE AFTER HIATAL HERNIA REPAIR WITH MESH3
Clinical frailty is a risk factor of adverse outcomes in patients with esophageal cancer undergoing esophagectomy: analysis of 2011–2017 US hospitals3
623 MINIMALLY INVASIVE VERSUS OPEN MCKEOWN FOR PATIENTS WITH ESOPHAGEAL CANCER: A RETROSPECTIVE STUDY3
326. REDUCTION OF ANASTOMOTIC LEAKAGE AFTER ESOPHAGECTOMY WITH RETROSTERNAL GASTRIC TUBE RECONSTRUCTION3
148: LAPAROSCOPIC FUNDOPLICATION FOR PARA-ESOPHAGEAL HERNIA REPAIR IMPROVES RESPIRATORY FUNCTION IN PATIENTS PRESENTING WITH DYSPNEA: A PROSPECTIVE COHORT STUDY3
549. LAPAROSCOPIC CARDIOPLASTY FOR FAILED PRIMARY TREATMENT OF ACHALASIA3
380. INTEGRATIVE TRANSCRIPTOMIC AND FUNCTIONAL ANALYSIS OF CHEMOTHERAPY RESISTANCE IN ESOPHAGEAL ADENOCARCINOMA3
177. BULKY LYMPHADENOPATHY IN ESOPHAGEAL CANCER: ASSESSING PATHOLOGICAL AND SURVIVAL OUTCOMES AFTER TREATMENT WITH CURATIVE INTENT3
Transition from esophagectomy to endoscopic therapy for early esophageal cancer3
112 ROBOT-ASSISTED MINIMALLY INVASIVE ESOPHAGECTOMY CAN BE PERFORMED EVEN IN LEARNING CURVE PERIOD; PROPENSITY SCORE MATCH ANALYSIS3
636 SHORT-TERM OUTCOME FOR HIGH-RISK PATIENTS AFTER ESOPHAGECTOMY3
303. THE TISSUE SYSTEMS PATHOLOGY-9 TEST PROVIDES CLINICALLY-IMPACTFUL RISK STRATIFICATION IN PATIENTS WITH BARRETT’S ESOPHAGUS: CLINICAL EXPERIENCE IN A MULTICENTER COHORT3
241. EVALUATION OF THE PYLORUS FOLLOWING GASTRIC CONDUIT RECONSTRUCTION IN OESOPHAGECTOMY USING IMPEDANCE PLANIMETRY—A SYSTEMATIC REVIEW WITH META-ANALYSIS3
474. MANOMETRIC IDENTIKIT OF A FUNCTIONING AND EFFECTIVE FUNDOPLICATION IN THE HIGH-RESOLUTION MANOMETRY ERA3
600. TREATMENT OUTCOME OF CLINICALLY UNRESECTABLE ESOPHAGEAL CANCER AFTER NEO-ADJUVANT CHEMOTHERAPY WITH DOCETAXEL, CISPLATIN AND 5-FLUOROURACIL3
555 VISCERAL OBESITY: PREVALENCE, AND IMPACT ON OPERATIVE AND ONCOLOGIC OUTCOMES IN THE CURATIVE MANAGEMENT OF ESOPHAGEAL CANCER3
303. A NOVEL ‘WATERFALL METHOD’ OF FILLING THE POSTERIOR MEDIASTINAL CAVITY AFTER ESOPHAGECTOMY USING OMENTAL FLAP IN RETROSTERNAL GASTRIC TUBE RECONSTRUCTION3
427. CAN WE OPTIMIZE THE RECOMMENDATIONS FOR FOLLOW-UP OF BARRETT’S ESOPHAGUS THROUGH CRITICAL ANALYSIS OF RISK FACTORS IN A SPECIFIC POPULATION?3
720 CONVENTIONAL AND SIMPLE METHODS OF MEASURING MEAN NOCTURNAL BASELINE IMPEDANCE SHOW EXCELLENT AGREEMENT3
222. ARE GASTRIC MAPPING BIOPSIES NECESSARY TO DETERMINE THE DISTAL RESECTION MARGIN FOR SIGNET RING ADENOCARCINOMAS OF THE OESOPHAGO-GASTRIC JUNCTION?3
184. INTRATHORACIC SIDE-OVERLAP ESOPHAGOGASTROSTOMY DURING MINIMALLY INVASIVE ESOPHAGECTOMY FOR ESOPHAGOGASTRIC JUNCTION CANCER3
343 EFFECTS OF PREOPERATIVE PNI (PROGNOSTIC NUTRITIONAL INDEX) AND POSTOPERATIVE INFLAMMATORY RESPONSE ON PROGNOSIS IN PATIENTS WITH ESOPHAGEAL CANCER3
515. EXOCRINE PANCREATIC FUNCTION IN PATIENTS AFTER ESOPHAGECTOMY; IS TREATMENT WITH PANCREATIC ENZYMES NECESSARY?3
Management of esophageal anastomotic leaks, a systematic review and network meta-analysis3
441. COMBINING LARYNGEAL ULTRASONOGRAPHY (LUSG) WITH VOICE ASSESSMENT OR INTRA-OPERATIVE NERVE MONITORING RESULTS ACCURATELY CONFIRMS NORMAL VOCAL CORD FUNCTION AFTER ESOPHAGECTOMY3
Pre-treatment differential correlation of gene expression and response to topical steroids in eosinophilic esophagitis2
771 IMPACT OF NATIONWIDE CENTRALIZATION OF ESOPHAGEAL, GASTRIC, AND PANCREATIC SURGERY ON TRAVEL DISTANCE AND EXPERIENCED BURDEN IN THE NETHERLANDS2
296. A BEGINNER’S THREE-YEAR LEARNING CURVE WITH ESOPHAGECTOMIES: A STUDY FROM A PERIPHERAL CANCER CENTRE IN NORTH-EAST INDIA2
604. REAL-WORLD MANAGEMENT AND OUTCOMES OF PATIENTS WITH NON METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA IN THE FREGAT DATABASE2
383. LOSS OF PERISTALTIC RESERVE DETERMINED BY MULTIPLE RAPID SWALLOWS CORRELATES WITH DYSPHAGIA AND POOR BOLUS TRANSIT IN INEFFECTIVE ESOPHAGEAL MOTILITY2
451. PREDICTIVE FACTORS FOR PNEUMONIA AND ANASTOMOTIC LEAK AFTER TRANSTHORACIC ESOPHAGECTOMY FOR CANCER AND FAILURE TO RESCUE ANALYSIS ON 1355 PATIENTS2
213. A NEW MANOMETRIC TOOL TO EVALUATE THE EFFICACY OF LAPAROSCOPIC ANTIREFLUX SURGERY2
496. OESOPHAGEAL STENTING IN BOERHAAVE SYNDROME: OUR EXPERIENCE2
Magnetic sphincter augmentation: considerations for use in Barrett’s esophagus2
410. THE RELATIONSHIP BETWEEN GASTRIC CONDUIT EMPTYING, FUNCTIONAL ANATOMY AND PERISTALSIS: A DETAILED ANALYSIS USING DYNAMIC MAGNETIC RESONANCE IMAGING2
Is proton-pump inhibitor effective in preventing postoperative bleeding after esophageal endoscopic submucosal dissection?2
243. IS MUCOSAL CHANGE IN COELIAC DISEASE RESTRICTED TO SMALL BOWEL? STUDY OF OESOPHAGEAL MUCOSAL CHANGES IN CHILDREN WITH COELIAC DISEASE2
698 ENDOLUMINAL VACUUM THERAPY (EVT) AS A TREATMENT FOR ESOPHAGEAL LEAKS; 10-YEARS’ EXPERIENCE FROM A TERTIARY UK ESPHAGOGASTRIC CENTRE2
552. LAPAROSCOPIC RE DO FUNDOPLICATION2
167. LYMPHATIC INVASION CAN PREDICT POSTOPERATIVE LYMPH NODE RECURRENCE IN PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA2
236. INDOCYANINE GREEN TRACHEOBRONCHIAL FLUORESCENCE (ICG-TBF) VIA NEBULIZATION DURING MINIMALLY INVASIVE ESOPHAGECTOMY -A NOVEL TECHNIQUE2
Sex differences in survival following surgery for esophageal cancer: A systematic review and meta-analysis2
557. POTENTIAL THERAPEUTIC TARGETS OF TRPV2 AND SLC12A2 IN ESOPHAGEAL ADENOCARCINOMA CANCER STEM CELLS2
622 CORRELATION ANALYSIS BETWEEN MAJOR FOOD GROUPS' CONSUMPTION AND THE RESULTS OF 24-HOURS OESOPHAGEAL PH-IMPEDANCE STUDIES2
802 PERIOPERATIVE AND SHORT-TERM OUTCOMES FOR PRIMARY ANTIREFLUX SURGERY: FUNDOPLICATION VS. RNY RECONSTRUCTION2
Sex- and gender-specific differences in symptoms and health-related quality of life among patients with gastroesophageal reflux disease2
406. A SYSTEMATIC REVIEW AND META-ANALYSIS ON THE USE OF ARTIFICIAL INTELLIGENCE IN THE ENDOSCOPIC DIAGNOSIS OF ESOPHAGEAL CANCER2
754. PATHOLOGICAL RESPONSE PREDICTS EFFICACY OF ADJUVANT FLOT CHEMOTHERAPY IN GASTROESOPHAGEAL CANCER: AN INTERNATIONAL COHORT STUDY2
Myotomy in sigmoid megaesophagus: is it applicable? A systematic review and meta-analysis2
556. PREDICTORS OF EARLY RECURRENCE AFTER OESOPHAGECTOMY AND NEOADJUVANT FLOT2
646 PREDICTING RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH OESOPHAGEAL ADENOCARCINOMA2
478. OVERVIEW ON USE OF THE TRANSCERVICAL MEDIASTINOSCOPIC APPROACH FOR MINIMALLY INVASIVE TREATMENT OF ESOPHAGEAL CANCER: ESTABLISHMENT OF INTERNATIONAL COLLABORATIVE GROUP2
453. THE EFFECTIVITY OF NEOADJUVANT CHEMORADIOTHERAPY IN ESOPHAGEAL ADENOCARCINOMA WITH PRESENCE OF EXTRACELLULAR MUCINE, SIGNET-RING CELLS OR POORLY COHESIVE CELLS2
635 ROBOTIC REDO FUNDUPLICATION FOR A TWO TIME RECURRENT HIATAL HERNIA. HOW WE DO?2
335. LONG TERM RISK FOR PROGRESSION TO NEOPLASIA FOR BARRETT’S ESOPHAGUS PATIENTS WITH VALIDATED LOW-GRADE DYSPLASIA OR INDEFINITE FOR DYSPLASIA2
378. FLOT VS ECX: A COMPARISON OF TWO NEOADJUVANT CHEMOTHERAPY REGIMEN’S EFFECTS ON SARCOPENIA IN ESOPHAGOGASTRIC ADENOCARCINOMA PATIENTS2
The risk of autism spectrum disorder and intellectual disability but not attention deficit/hyperactivity disorder is increased in individuals with esophageal atresia2
Screening for synchronous esophageal second primary tumors in patients with head and neck cancer2
Is systematic formal crural repair mandatory at the time of magnetic sphincter augmentation implantation?2
113 CONCURRENT SURGICAL TREATMENT STRATEGY FOR SYNCHRONOUS ESOPHAGEAL CANCER AND HEAD AND NECK CANCER IN OUR INSTITUTION2
333. TECHNICAL CONSIDERATIONS IN UPPER-GI RECONSTRUCTION – A CASE SERIES2
Research gap in esophageal achalasia: a narrative review2
534. EVALUATION OF SURGICAL OUTCOMES IN ROBOTIC-ASSISTED ESOPHAGECTOMY2
215 LOCATION OF ANASTOMOSIS BEHIND THE STERNOCLAVICULAR JOINT INCREASES THE INCIDENCE OF ANASTOMOTIC STENOSIS IN RETROSTERNAL RECONSTRUCTION AFTER ESOPHAGECTOMY2
549. CLINICAL IMPLICATIONS OF SELECTIVE RIGHT PARATRACHEAL LYMPH NODE DISSECTION IN PATIENTS WITH EARLY-STAGE ESOPHAGEAL CANCER: PROPENSITY-SCORE MATCHED ANAYLSIS2
280 CONVERSION SURGERY FOR BORDERLINE T4 ESOPHAGEAL CANCER2
256. PROGNOSIS AND RISK FACTORS FOR SUPRACLAVICULAR LYMPH NODE METASTASIS IN PATIENTS WITH MIDDLE AND LOWER THORACIC ESOPHAGEAL CANCER2
385 MIR-24-3P REGULATES CDX2 DURING THE PROCESS OF INTESTINALIZATION OF THE CARDIAC-TYPE EPITHELIUM IN A HUMAN MODEL OF BARRETT’S ESOPHAGUS2
788 VARIABLE GEOGRAPHICAL DIFFERENCES OF AMBULATORY ESOPHAGEAL REFLUX MONITORING IN MEXICO2
415. A WEBCAST FOR THE EDUCATION AND INFORMATION OF PATIENTS WITH BARRETT’S ESOPHAGUS AND BARRETT’S CANCER2
143. NEOADJUVANT CHEMORADIOTHERAPY VERSUS CHEMOTHERAPY FOR THE TREATMENT OF LOCALLY ADVANCED ESOPHAGEAL ADENOCARCINOMA IN THE EUROPEAN MULTICENTER ENSURE STUDY2
144. OPTIMIZING MEDIASTINAL ACCESS FOR RADICAL ESOPHAGECTOMY: A BILATERAL CERVICAL AND TRANSHIATAL APPROACH TO RESECT ESOPHAGEAL CANCER1
Laparoscopic ischemic conditioning prior esophagectomy in selected patients: the ISCON trial1
650. ROBOTIC ESOPHAGEAL LEIOMYOMA ENUCLEATION1
254 LYMPH NODE DISSECTION IN T1 AND T2 ESOPHAGEAL SQUAMOUS CELL CARCINOMA: MINIMALLY INVASIVE ESOPHAGECTOMY VERSUS OPEN SURGERY1
593. UPPER MEDIASTINAL LYMPHADENECTOMY IN PRONE POSITION TOTALLY MINIMALLY INVASIVE ESOPHAGECTOMY1
5: LOCAL ENDOSCOPIC RESECTION IS INFERIOR TO GASTRECTOMY FOR EARLY CLINICAL STAGE T1A AND T1B GASTRIC ADENOCARCINOMA: A PROPENSITY-MATCHED STUDY1
270 LYMPHADENECTOMY ALONG BILATERAL RECURRENT LARYNGEAL NERVE UNDER SINGLE-PORT INFLATABLE MEDIASTINOSCOPY THROUGH LEFT NECK APPROACH1
431. RARE CASE OF CONTAINED ESOPHAGEAL PERFORATION IN LONG STANDING ACHALASIA CARDIA AND ITS SUCCESSFUL MANAGEMENT1
169. PROPENSITY SCORE MATCHING ANALYSIS OF THE EFFECT ON PROGNOSIS OF PROPHYLACTIC NECK DISSECTION FOR ESOPHAGEAL CANCER1
571. ESOPHAGEAL PERFORATION AFTER LOBECTOMY: PADLOCK CLIP TO THE RESCUE1
464. MINIMALLY INVASIVE IVOR LEWIS ESOPHAGECTOMY IN THE ELDERLY PATIENT: A MULTICENTER RETROSPECTIVE MATCHED-COHORT STUDY1
18. REFLUX OF DUODENAL CONTENTS INDUCES ESOPHAGEAL CARCINOGENESIS (SCC, ADC)1
663 QUANTITATIVE PERFUSION ASSESSMENT TO PREDICT ANASTOMOTIC LEAK AFTER ESOPHAGECTOMY1
416. BIOMARKER IDENTIFICATION FOR CHEMOTHERAPY RESPONSE PREDICTION IN BARRETT’S CARCINOMA PATIENTS BY AN INFLAMMATORY-RELATED PLASMA PROTEIN PROFILING1
590 VARIATION IN RECEIPT OF THERAPY AND SURVIVAL WITH PROVIDER-VOLUME IN NON-CURATIVE ESOPHAGO-GASTRIC CANCER: A POPULATION-BASED ANALYSIS1
334. DEFINITION OF SEVERE BENIGN OESOPHAGEAL STRICTURES AND IDENTIFICATION OF ASSOCIATED RISK FACTORS1
366. SURGERY VERSUS NON-SURGICAL TREATMENT FOR THORACIC ESOPHAGEAL CANCER IN PATIENTS OLDER THAN 70 YEARS: A RETROSPECTIVE ANALYSIS OF 749 CASES1
Long-term fear of cancer recurrence in patients treated endoscopically for early Barrett’s neoplasia1
309. SURGICAL TREATMENT FOR THE RECURRENT SITE OF ESOPHAGEAL CANCER AFTER ESOPHAGECTOMY1
Immunonutrition to improve the quality of life of upper gastrointestinal cancer patients undergoing neoadjuvant treatment prior to surgery (NEOIMMUNE): double-blind randomized controlled multicenter c1
267. IDENTIFYING CANCER-ASSOCIATED FIBROBLAST POPULATIONS DRIVING THERAPY RESISTANCE IN GASTROESOPHAGEAL ADENOCARCINOMA1
623. A NEW PROGNOSTIC EVALUATION OF POSTOPERATIVE ESOPHAGEAL CANCER: LONG-TERM FLAIL INVESTIGATION1
267 INTESTINAL STEM CELL MARKERS AND ITS POTENTIAL USE IN THE CLINICOPATHOLOGICAL SETTING OF ESOPHAGEAL ADENOCARCINOMA1
391. MINIMALLY INVASIVE ESOPHAGECTOMY IN PRONE POSITION. INITIAL EXPERIENCE OF NATIONAL CANCER INSTITUTE MEXICO1
833 CLINICAL PATHWAY DEVELOPMENT AND IMPLEMENTATION FOR THE MANAGEMENT OF CHYLE LEAK FOLLOWING OESOPHAGECTOMY: THE OXFORD EXPERIENCE1
Criteria of patient selection for magnetic sphincter augmentation1
376. DOUBLE FLAP RECONSTRUCTION (KAMIKAWA TECHNIQUE) AS ANTI-REFLUX MECHANISM AFTER GASTROESOPHAGEAL SURGERY1
347. LASER CAPTURE MICRODISSECTION AND WHOLE GENOME SEQUENCING OF ESOPHAGEAL ADENOCARCINOMA SAMPLES WITH MINIMAL TUMOUR1
176: YAP/TAZ ACTIVATION IS A MECHANISM OF TUMOR PROGRESSION IN THE POORLY COHESIVE GASTRIC CANCER PHENOTYPE1
292. SPECIFIC METHYLATION MARKERS ASSOCIATED WITH CHANGES IN GENE EXPRESSION DISTINGUISH EAC AND SUB-TYPES OF BE PATIENTS1
494. GIANT GASTROINTESTINAL STROMAL TUMOR OF THE ESOPHAGUS: REPORT OF TWO CASES1
300. RETROSPECTIVE STUDY FOR EVALUATING IMPACT OF NEOADJUVANT THERAPY USING CDDP +5-FU TOWARD ELDERLY ESOPHAGEAL CANCER PATIENTS1
377. NEOADJUVANT CARBOPLATIN/PACLITAXEL VERSUS 5-FLUOROURACIL/CISPLATIN IN COMBINATION WITH RADIOTHERAPY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A MULTICENTER COMPARATIVE STUDY1
Empiric proton pump inhibitor therapy after esophageal food impaction may mask eosinophilic esophagitis diagnosis at follow-up1
323. CLINICAL CHARACTERISTICS OF HIATAL HERNIA WITH ANEMIA AND SIGNIFICANCE OF SURGICAL REPAIR1
399. CURRENT PRACTICE IN ANTIREFLUX AND HIATAL HERNIA SURGERY: EXPLORATION OF THE BELGIAN FIELD1
756 LONG-TERM OUTCOME AFTER ENDOSCOPIC SUBMUCOSAL DISSECTION FOR ENTIRE CIRCUMFERENTIAL CT1AN0M0 ESOPHAGEAL SQUAMOUS CELL CARCINOMA1
397. LEFT PILLAR PINCHING TECHNIQUE FOR MINIMALLY INVASIVE REPAIR OF PARA-CONDUIT HERNIA1
792 OUTCOMES AFTER TOTALLY MINIMALLY INVASIVE VERSUS HYBRID OR OPEN IVOR LEWIS ESOPHAGECTOMY: RESULTS FROM THE INTERNATIONAL ESODATA STUDY GROUP.1
453. TREATMENT AND SURVIVAL OF PATIENTS WITH A POSITIVE RESECTION MARGIN AFTER NEOADJUVANT CHEMORADIOTHERAPY AND ESOPHAGECTOMY1
558 OUTCOMES OF PER ORAL ENDOSCOPIC MYOTOMY IN ACHALASIA IN PATIENTS WITH END-STAGE ESOPHAGUS1
628. THE BEST METHOD OF THE GASTRIC TUBE RECONSTRUCTION AFTER ESOPHAGECTOMY1
648. HYPOXIA-INDUCIBLE FACTOR 1α (HIF-1α) STIMULATES THE PROGRESSION OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA BY ACTIVATING THE WNT/β-CATENIN SIGNALLING PATHWAY1
153 THE CLINICAL SIGNIFICANCE OF INCOMPLETE BOLUS CLEARANCE IN PATIENTS WITH DYSPHAGIA1
424. EXPRESSION OF KCNB1 AND ITS RELATION TO TUMOR PROGRESSION IN ESOPHAGEAL CANCER1
362 SUPERIOR POLAR GASTRECTOMY ASSOCIATED WITH ANTI-REFLUX TECHNIQUE: CASE REPORT1
249. AUTOMATED PREDICTION SYSTEM USING COMPUTER VISION FOR ESOPHAGEAL STRICTURE AFTER ESOPHAGEAL ENDOSCOPIC RESECTION1
137. THE COMPARISON OF SHORT-TERM OUTCOMES BETWEEN NEOADJUVANT CHEMOTHERAPY COMBINED WITH IMMUNOTHERAPY AND NEOADJUVANT CHEMORADIOTHERAPY FOR ESOPHAGEAL SQUAMOUS CANCER1
436. USEFULNESS OF INTRAOPERATIVE CONTINUOUS NERVE MONITORING IN TRANSMEDIASTINAL MINIMALLY INVASIVE ESOPHAGECTOMY1
444 CORRELATION BETWEEN PATHOLOGIC COMPLETE RESPONSE TO NEOADJUVANT THERAPY AND RECURRENCE IN PATIENTS WITH ESOPHAGEAL CANCER1
41. HIGH COMPREHENSIVE COMPLICATION INDEX AFTER MINIMALLY INVASIVE ESOPHAGECTOMY ASSOCIATED WITH POOR SHORT-TERM AND LONG-TERM OUTCOME: A PROPENSITY SCORE MATCHING ANALYSIS1
Reoperative surgery after magnetic sphincter augmentation1
506. MANAGEMENT OF POST INTUBATION TRACHEO-ESOPHAGEAL FISTULA. HOW, WHEN AND WHY TO FACE OFF A POTENTIALLY FATAL INJURY1
275. PREOPERATIVE 3D-CT EVALUATION OF THE BRONCHIAL ARTERIES IN TRANSMEDIASTINAL RADICAL ESOPHAGECTOMY FOR ESOPHAGEAL CANCER1
421. THE STAPLED ANASTOMOSIS IN ESOPHAGECTOMY: NO DIFFERENCES IN LEAKAGE AND STRICTURE-RATES BETWEEN THE 25 MM AND 28 MM CIRCULAR STAPLER1
Segmental overlap is common in eosinophilic gastrointestinal diseases and impacts clinical presentation and treatment1
0.10976409912109